Allen L Hwang1, Kevin Haynes, Wei-Ting Hwang, Yu-Xiao Yang. 1. From the *Division of Gastroenterology, Hospital at the University of Pennsylvania; and †Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA.
Abstract
OBJECTIVES: Our aim was to determine the effect of metformin exposure on survival in patients with advanced pancreatic adenocarcinoma (PAC). METHODS: A retrospective cohort study was conducted using The Health Improvement Network, a primary care electronic medical record database from the United Kingdom (2003-2010). The study cohort included all subjects with a diagnostic code for incident PAC and a preexisting diagnosis of type 2 diabetes mellitus. Subjects were classified as exposed if they were prescribed metformin around the time of PAC diagnosis (between 6 months prior and 1 month after). A secondary analysis was performed only on exposed subjects without prior (ie, 6 months before PAC diagnosis) exposure to metformin. The primary outcome was overall survival. The analysis was performed using univariate and multivariable Cox proportional hazards models. RESULTS: The study included 516 subjects with preexisting type 2 diabetes mellitus and PAC, 247 of which were exposed to metformin. In univariate and multivariable analysis, there was no difference in survival between those exposed and those unexposed to metformin in the primary analysis (hazards ratio, 1.11 [0.89-1.38], P = 0.367) or the secondary analysis (hazards ratio, 1.09 [0.80-1.47], P = 0.585). CONCLUSIONS: Metformin use is not associated with improved survival in subjects with advanced PAC.
OBJECTIVES: Our aim was to determine the effect of metformin exposure on survival in patients with advanced pancreatic adenocarcinoma (PAC). METHODS: A retrospective cohort study was conducted using The Health Improvement Network, a primary care electronic medical record database from the United Kingdom (2003-2010). The study cohort included all subjects with a diagnostic code for incident PAC and a preexisting diagnosis of type 2 diabetes mellitus. Subjects were classified as exposed if they were prescribed metformin around the time of PAC diagnosis (between 6 months prior and 1 month after). A secondary analysis was performed only on exposed subjects without prior (ie, 6 months before PAC diagnosis) exposure to metformin. The primary outcome was overall survival. The analysis was performed using univariate and multivariable Cox proportional hazards models. RESULTS: The study included 516 subjects with preexisting type 2 diabetes mellitus and PAC, 247 of which were exposed to metformin. In univariate and multivariable analysis, there was no difference in survival between those exposed and those unexposed to metformin in the primary analysis (hazards ratio, 1.11 [0.89-1.38], P = 0.367) or the secondary analysis (hazards ratio, 1.09 [0.80-1.47], P = 0.585). CONCLUSIONS:Metformin use is not associated with improved survival in subjects with advanced PAC.
Authors: W Scheithauer; B Schüll; H Ulrich-Pur; K Schmid; M Raderer; K Haider; W Kwasny; D Depisch; B Schneeweiss; F Lang; G V Kornek Journal: Ann Oncol Date: 2003-01 Impact factor: 32.976
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: Navid Sadeghi; James L Abbruzzese; Sai-Ching J Yeung; Manal Hassan; Donghui Li Journal: Clin Cancer Res Date: 2012-03-31 Impact factor: 12.531
Authors: David Cunningham; Ian Chau; Deborah D Stocken; Juan W Valle; David Smith; William Steward; Peter G Harper; Janet Dunn; Catrin Tudur-Smith; Julia West; Stephen Falk; Adrian Crellin; Fawzi Adab; Joyce Thompson; Pauline Leonard; Joe Ostrowski; Martin Eatock; Werner Scheithauer; Richard Herrmann; John P Neoptolemos Journal: J Clin Oncol Date: 2009-10-26 Impact factor: 44.544
Authors: Viviane Hess; Marc Salzberg; Markus Borner; Rudolf Morant; Arnaud D Roth; Christian Ludwig; Richard Herrmann Journal: J Clin Oncol Date: 2003-01-01 Impact factor: 44.544
Authors: S Amin; G Mhango; J Lin; A Aronson; J Wisnivesky; P Boffetta; Aimee L Lucas Journal: Am J Gastroenterol Date: 2016-07-19 Impact factor: 10.864
Authors: Inaya Ahmed; Adam Ferro; Alan Cohler; John Langenfeld; Sujani G Surakanti; Joseph Aisner; Wei Zou; Bruce G Haffty; Salma K Jabbour Journal: J Thorac Dis Date: 2015-03 Impact factor: 2.895